nnoxel Lifesciences, based in Vadodara, India, is a pharmaceutical company focused on the sterile manufacturing of injectable vials, pre-filled syringes, and oral liquid formulations—both aseptically processed and terminally sterilized. With in-house capabilities in research, formulation development, and production, Innoxel specializes in advanced drug delivery systems, particularly in critical care and oncology therapies.
Targeting highly regulated international markets like the United States, Innoxel is committed to delivering products that meet the highest global quality standards, contributing to India’s growing presence in the global pharmaceutical landscape.
Founded in 2020 as a greenfield project, Innoxel Lifesciences was thoughtfully designed and built from the ground up. The facility is now fully operational and aligned with EU GMP, UK MHRA, and US FDA compliance requirements. The company’s first ANDA submissions to the US FDA are expected in Q1 2024, paving the way for a potential US FDA inspection in early 2025.
